Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy

Open access

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related mortality and chemoresistance is a major medical issue. The epithelial-to-mesenchymal transition (EMT) is the primary step in the emergence of the invasive phenotype and the Hedgehog-GLI (HH-GLI) and NOTCH signaling pathways are associated with poor prognosis and EMT in CRC. CRC cell lines harboring KRAS or BRAF mutations, grown as monolayers and organoids, were treated with the chemotherapeutic agent 5-Fluorouracil (5-FU) alone or combined with HH-GLI and NOTCH pathway inhibitors GANT61 and DAPT, or arsenic trioxide (ATO) to inhibit both pathways. Treatment with 5-FU led to the activation of HH-GLI and NOTCH pathways in both models. In KRAS mutant CRC, HH-GLI and NOTCH signaling activation co-operate to enhance chemoresistance and cell motility, while in BRAF mutant CRC, the HH-GLI pathway drives the chemoresistant and motile phenotype. We then showed that 5-FU promotes the mesenchymal and thus invasive phenotype in KRAS and BRAF mutant organoids and that chemosensitivity could be restored by targeting the HH-GLI pathway in BRAF mutant CRC or both HH-GLI and NOTCH pathways in KRAS mutant CRC. We suggest that in KRAS-driven CRC, the FDA-approved ATO acts as a chemotherapeutic sensitizer, whereas GANT61 is a promising chemotherapeutic sensitizer in BRAF-driven CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15051471

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 HH-GLI and NOTCH signaling pathways sustain resistance to 5-FU in KRAS mutant CRC cells. (A) Western blot analysis of NOTCH1 Intracellular domain (NOTCH1 ID), GLI1 and cleaved-PARP (c-PARP) in HCT116 cells after 5-FU treatment in combination with GANT61 and DAPT. Numbers indicate intensity ratio of bands. Bar graphs show densitometric quantification of the band intensity values normalized to the loading control. * p < 0.05; ** p < 0.01; *** p < 0.001 versus control; § p < 0.05 versus 5-FU; §§ p < 0.01; §§§ p < 0.001 (Two-way ANOVA test). Uncropped full scan in Supplementary Figure S4. (B) Evaluation of cell viability by Trypan Blue exclusion assay in HCT116 after 5-FU treatment with or without GANT61 and/or DAPT; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test). (C) Correlation analysis between GLI1 and NOTCH1 expression from dataset interrogated on R2 platform, as indicated in main text. (D) Western blot analysis of GLI1, NOTCH1 ID and c-PARP in HCT116 cells treated with 5-FU and ATO. Numbers indicate intensity ratio of bands. Bar graphs show densitometric quantification of the band intensity values normalized to the loading control; * p < 0.05; ** p < 0.01; (Two-way ANOVA test). (E) Transwell invasion assay in HCT116 cells treated with 5-FU, ATO and the combined treatment and control group (CTRL). Scale bar 150 µm. ** p < 0.01; *** p < 0.001; versus control; §§§ p < 0.001 (One-way ANOVA test).
Figure 1 HH-GLI and NOTCH signaling pathways sustain resistance to 5-FU in KRAS mutant CRC cells. (A) Western blot analysis of NOTCH1 Intracellular domain (NOTCH1 ID), GLI1 and cleaved-PARP (c-PARP) in HCT116 cells after 5-FU treatment in combination with GANT61 and DAPT. Numbers indicate intensity ratio of bands. Bar graphs show densitometric quantification of the band intensity values normalized to the loading control. * p < 0.05; ** p < 0.01; *** p < 0.001 versus control; § p < 0.05 versus 5-FU; §§ p < 0.01; §§§ p < 0.001 (Two-way ANOVA test). Uncropped full scan in Supplementary Figure S4. (B) Evaluation of cell viability by Trypan Blue exclusion assay in HCT116 after 5-FU treatment with or without GANT61 and/or DAPT; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test). (C) Correlation analysis between GLI1 and NOTCH1 expression from dataset interrogated on R2 platform, as indicated in main text. (D) Western blot analysis of GLI1, NOTCH1 ID and c-PARP in HCT116 cells treated with 5-FU and ATO. Numbers indicate intensity ratio of bands. Bar graphs show densitometric quantification of the band intensity values normalized to the loading control; * p < 0.05; ** p < 0.01; (Two-way ANOVA test). (E) Transwell invasion assay in HCT116 cells treated with 5-FU, ATO and the combined treatment and control group (CTRL). Scale bar 150 µm. ** p < 0.01; *** p < 0.001; versus control; §§§ p < 0.001 (One-way ANOVA test).CC BY · PubMed Central
Figure 2 HH-GLI signaling pathway sustains resistance to 5-FU in BRAF mutant CRC cells. (A) Western blot analysis of NOTCH1 Intracellular domain (NOTCH1 ID), GLI1 and cleaved-PARP (c-PARP) in HT29 cells after 5-FU treatment in combination with GANT61 and DAPT. Numbers indicate intensity ratio of bands. Bar graphs show densitometrically quantified band intensity values normalized to the loading control; * p < 0.05 ** p < 0.01; *** p < 0.001; § p < 0.05 versus 5-FU; §§ p < 0.01 (Two-way ANOVA test). Uncropped full scan in Supplementary Figure S5. (B) Evaluation of cell viability by Tripan Blue exclusion assay in HT29 after 5-FU treatment in combination with GANT61 and DAPT; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test). (C) Correlation analysis between GLI1 and NOTCH1 expression from dataset interrogated on R2 platform as indicated in main text. (D) Transwell invasion assay in HT29 cells treated with 5-FU, GANT61, the combined treatment and control group (CTRL); Scale bar 150 µm; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test).
Figure 2 HH-GLI signaling pathway sustains resistance to 5-FU in BRAF mutant CRC cells. (A) Western blot analysis of NOTCH1 Intracellular domain (NOTCH1 ID), GLI1 and cleaved-PARP (c-PARP) in HT29 cells after 5-FU treatment in combination with GANT61 and DAPT. Numbers indicate intensity ratio of bands. Bar graphs show densitometrically quantified band intensity values normalized to the loading control; * p < 0.05 ** p < 0.01; *** p < 0.001; § p < 0.05 versus 5-FU; §§ p < 0.01 (Two-way ANOVA test). Uncropped full scan in Supplementary Figure S5. (B) Evaluation of cell viability by Tripan Blue exclusion assay in HT29 after 5-FU treatment in combination with GANT61 and DAPT; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test). (C) Correlation analysis between GLI1 and NOTCH1 expression from dataset interrogated on R2 platform as indicated in main text. (D) Transwell invasion assay in HT29 cells treated with 5-FU, GANT61, the combined treatment and control group (CTRL); Scale bar 150 µm; * p < 0.05, ** p < 0.01 versus CTRL (One-way ANOVA test).CC BY · PubMed Central
Figure 3 5-FU increases motility in CRC organoids. (A) Workflow for CRC organoid growth. (B) Brightfield image of HCT116 and HT29 organoids (respectively oHCT116 and oHT29) after 7 days of culture. (C) Quantitative real-time PCR of HES1, GLI1, c-MET expressed in HCT116 and HT29 cultured in monolayer and as organoids; * p < 0.05 versus CTRL; ** p < 0.01 (Two-way ANOVA test). (D) Fluorescent images of GFP-labeled HCT116 on sequential hours, scale bar 200 µm. Supplementary Videos S1 and S2 of time lapse experiments are available in Supplementary Figure S3A,B. (E) Violin plot of the diffusion parameters obtained from the single cell trajectories for CTRL and 5-FU-treated organoids. Kolmogorov–Smirnov test p-value 0.0032.
Figure 3 5-FU increases motility in CRC organoids. (A) Workflow for CRC organoid growth. (B) Brightfield image of HCT116 and HT29 organoids (respectively oHCT116 and oHT29) after 7 days of culture. (C) Quantitative real-time PCR of HES1, GLI1, c-MET expressed in HCT116 and HT29 cultured in monolayer and as organoids; * p < 0.05 versus CTRL; ** p < 0.01 (Two-way ANOVA test). (D) Fluorescent images of GFP-labeled HCT116 on sequential hours, scale bar 200 µm. Supplementary Videos S1 and S2 of time lapse experiments are available in Supplementary Figure S3A,B. (E) Violin plot of the diffusion parameters obtained from the single cell trajectories for CTRL and 5-FU-treated organoids. Kolmogorov–Smirnov test p-value 0.0032.CC BY · PubMed Central
Figure 4 HH-GLI and NOTCH inhibition impairs 5-FU-driven mesenchymal phenotype in KRASG13D-driven CRC organoids. (A) Brightfield image of oHCT116 treated with 5-FU, ATO, their combination and the control group (CTRL); Scale bar 150 µm; * p < 0.05 versus CTRL; §§ p < 0.01 versus 5-FU (One-way ANOVA test). (B) Quantitative real-time PCR of stem markers expressed in oHCT116 treated with 5-FU, ATO, their combination and the control group (CTRL). mRNA levels of ABCG2, CD133a and c-MET expressed in oHCT116 were expressed in arbitrary units; * p < 0.05 versus CTRL; §§ p < 0.01 versus 5-FU (Two-way ANOVA test). (C) Whole-mount immunofluorescence staining of oHCT116 stained with phalloidin-594 (F-actin, red), vimentin (mesenchymal marker, green) and DNA (DAPI). Images were analyzed by using the program Zeiss ZEN 2.3 blue edition. Scale bar 200 µm.
Figure 4 HH-GLI and NOTCH inhibition impairs 5-FU-driven mesenchymal phenotype in KRASG13D-driven CRC organoids. (A) Brightfield image of oHCT116 treated with 5-FU, ATO, their combination and the control group (CTRL); Scale bar 150 µm; * p < 0.05 versus CTRL; §§ p < 0.01 versus 5-FU (One-way ANOVA test). (B) Quantitative real-time PCR of stem markers expressed in oHCT116 treated with 5-FU, ATO, their combination and the control group (CTRL). mRNA levels of ABCG2, CD133a and c-MET expressed in oHCT116 were expressed in arbitrary units; * p < 0.05 versus CTRL; §§ p < 0.01 versus 5-FU (Two-way ANOVA test). (C) Whole-mount immunofluorescence staining of oHCT116 stained with phalloidin-594 (F-actin, red), vimentin (mesenchymal marker, green) and DNA (DAPI). Images were analyzed by using the program Zeiss ZEN 2.3 blue edition. Scale bar 200 µm.CC BY · PubMed Central
Figure 5 HH-GLI inhibition impairs 5-FU-driven mesenchymal phenotype in BRAFV600E-driven CRC organoids. (A) Brightfield image of oHT29 treated with 5-FU, GANT61, their combination and the control group (CTRL); Scale bar 150µm; * p < 0.05 versus Ctrl; §§ p < 0.01 versus 5-FU (One-way ANOVA test). (B) Quantitative real-time PCR of ABCG2, CD133a and c-MET expressed in oHT29 were expressed in arbitrary units. Data are representative of three independent experiments, * p < 0.05 versus Ctrl; §§ p < 0.01 versus 5-FU (Two-way ANOVA test). (C) Whole-mount immunofluorescence of HT29 organoids stained using phalloidin-594 (f-actin, red), vimentin (mesenchymal marker, green) and DNA (DAPI). Images were analyzed by using the program Zeiss ZEN 2.3 blue edition. Scale bar 200 µm.
Figure 5 HH-GLI inhibition impairs 5-FU-driven mesenchymal phenotype in BRAFV600E-driven CRC organoids. (A) Brightfield image of oHT29 treated with 5-FU, GANT61, their combination and the control group (CTRL); Scale bar 150µm; * p < 0.05 versus Ctrl; §§ p < 0.01 versus 5-FU (One-way ANOVA test). (B) Quantitative real-time PCR of ABCG2, CD133a and c-MET expressed in oHT29 were expressed in arbitrary units. Data are representative of three independent experiments, * p < 0.05 versus Ctrl; §§ p < 0.01 versus 5-FU (Two-way ANOVA test). (C) Whole-mount immunofluorescence of HT29 organoids stained using phalloidin-594 (f-actin, red), vimentin (mesenchymal marker, green) and DNA (DAPI). Images were analyzed by using the program Zeiss ZEN 2.3 blue edition. Scale bar 200 µm.CC BY · PubMed Central
Figure 6 Hedgehog-Gli and NOTCH pathways sustain chemoresistance and the mesenchymal phenotype in CRC. Model of the activity of the Hedgehog-GLI and NOTCH pathways after chemotherapy stress in BRAFV600E and KRASG13D models. In KRAS-driven CRC, the chemotherapy stress activates both HH-GLI and NOTCH, which independently sustain the EMT program; in BRAF-driven CRC, chemotherapy stress induces the activation of the HH-GLI pathway, which in turn sustains the activation of NOTCH1 signaling, determining the acquisition of the EMT phenotype.
Figure 6 Hedgehog-Gli and NOTCH pathways sustain chemoresistance and the mesenchymal phenotype in CRC. Model of the activity of the Hedgehog-GLI and NOTCH pathways after chemotherapy stress in BRAFV600E and KRASG13D models. In KRAS-driven CRC, the chemotherapy stress activates both HH-GLI and NOTCH, which independently sustain the EMT program; in BRAF-driven CRC, chemotherapy stress induces the activation of the HH-GLI pathway, which in turn sustains the activation of NOTCH1 signaling, determining the acquisition of the EMT phenotype.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 28

Metadata

Authors
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., Spinello, Z., Vacca, A., De Smaele, E., Venneri, M. A., Ferretti, E., Masuelli, L., & Po, A.
Affiliations
  • Sapienza University of Rome (IT)
  • Università degli Studi di Enna Kore (IT)
  • Italian Institute of Technology (IT)
  • Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
  • Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy
Venue
Cancers
Publisher
MDPI AG
Published
2023-02-25
Volume
15
Issue
5
Pages
1471
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4322502598
Cited by
27
References
49
Citations by year
2026: 7 · 2025: 8 · 2024: 8 · 2023: 4
FWCI
2.41
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
Funders
  • Sapienza University of Rome (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
  • Sapienza Ateneo 2021 (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
  • Istituto Pasteur Italia—Fondazione Cenci Bolognetti (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
  • Project LOCALSCENT (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
  • Call POR-FESR “Gruppi di Ricerca 2020” (2021, RM12117A7F986146, 20203AMKTW, A0375-2020-36549)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
Keywords
colorectal cancer, chemoresistance, Hedgehog-Gli signaling, Notch signaling, epithelial-mesenchymal transition, tumor invasion, 5-fluorouracil, GANT61, DAPT, arsenic trioxide, KRAS mutation, BRAF mutation, colorectal organoids, chemosensitization, cell motility

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy. https://app.cochat.ai/papers/10.3390/cancers15051471
The paper
Citarella, A., Catanzaro, G., Besharat, Z. M., Trocchianesi, S., Barbagallo, F., Gosti, G., Leonetti, M., Di Fiore, A., Coppola, L., Autilio, T. M., Spinello, Z., Vacca, A., De Smaele, E., Venneri, M. A., Ferretti, E., Masuelli, L., & Po, A. (2023). Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy. Cancers. https://doi.org/10.3390/cancers15051471

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.